Breaking Finance News

ValuEngine upgraded Incyte Corporation (NASDAQ:INCY) to Hold in a report released today.

ValuEngine has upgraded Incyte Corporation (NASDAQ:INCY) to Hold in a report released on 6/02/2017.

Just yesterday Incyte Corporation (NASDAQ:INCY) traded -0.07% lower at $130.15. Incyte Corporation’s 50-day moving average is $118.07 and its 200-day moving average is $125.44. The last stock price is up -8.97% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.03% over the same time period. 1,571,603 shares of INCY traded hands, up from an average trading volume of 1,536,000

Recent Performance Chart

Incyte Corporation (NASDAQ:INCY)

Incyte Corporation has 52 week low of $83.01 and a 52 week high of $153.15 and has a market capitalization of $0.

In addition to ValuEngine reporting its stock price target, a total of 14 brokerages have issued a ratings update on the company. The average stock price target is $91.36 with 7 brokerages rating the stock a strong buy, 8 brokerages rating the stock a buy, 1 brokerage rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.

Brief Synopsis On Incyte Corporation (NASDAQ:INCY)

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.